Immutep Ltd (IMMP) is a biotechnology company headquartered in Sydney, Australia, renowned for its clinical and preclinical product portfolio developments. The company is a global leader when it comes to developing innovative immunotherapeutic products for cancer and autoimmune diseases with strong potential for market growth.
Founded in 1987, the company was originally known as Prima BioMed Ltd., but it rebranded as imMuteP in 2017 to reflect its focus on immune-oncology. It engages in manufacturing cutting-edge therapeutics used in the treatment of serious diseases that affect the human immune system, utilizing its expertise in LAG-3, a vital immune checkpoint that plays a critical role in the body's immune response.
Immutep’s proprietary product portfolio is built around a set of technologies that leverage Lymphocyte Activation Gene-3 (LAG-3) or CD223 which is a critical immune checkpoint for cancer immunity. These LAG-3 products include lead product candidate, eftilagimod alpha (efti or IMP321), a soluble LAG-3 protein that modulates the immune system to amplify anti-cancer immune responses.
The company’s key product candidates besides eftilagimod alpha include IMP761, an antibody product that suppresses the immune system and is being developed for the treatment of autoimmune diseases, and several partnered LAG-3 product candidates in development with big pharmaceutical companies like GlaxoSmithKline and Novartis Oncology.
Immutep has always taken a unique approach towards transforming the treatment of serious diseases, thereby arranging strategic partnerships and collaborations with other leading biotechnology and pharmaceutical companies around the world. Strong R&D investment with dedicated commitment towards innovation stands as a testimony to Immutep’s rise in the biopharmaceutical realm.
At the financial front, Immutep Ltd (IMMP) is listed on the NASDAQ and is also included in the Australian Securities Exchange. Creating shareholder value while focusing on the needs of the patients, this publicly traded company ensures broad access to its novel treatments.
From its inception until the present, Immutep has made significant contributions to medical research and the development of next-generation immunotherapy products. Its dedication to innovation and medical advancements has positioned it as a leader in the global biopharmaceutical industry, promising a healthier future for patients worldwide.